CN111141913A - Ceruloplasmin detection kit and preparation method thereof - Google Patents
Ceruloplasmin detection kit and preparation method thereof Download PDFInfo
- Publication number
- CN111141913A CN111141913A CN202010000861.5A CN202010000861A CN111141913A CN 111141913 A CN111141913 A CN 111141913A CN 202010000861 A CN202010000861 A CN 202010000861A CN 111141913 A CN111141913 A CN 111141913A
- Authority
- CN
- China
- Prior art keywords
- reagent
- ceruloplasmin
- solution
- latex
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100023321 Ceruloplasmin Human genes 0.000 title claims abstract description 68
- 108010075016 Ceruloplasmin Proteins 0.000 title claims abstract description 68
- 238000001514 detection method Methods 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 76
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 62
- 238000002156 mixing Methods 0.000 claims abstract description 42
- 239000004816 latex Substances 0.000 claims abstract description 38
- 229920000126 latex Polymers 0.000 claims abstract description 38
- 239000007853 buffer solution Substances 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 13
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 13
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012528 membrane Substances 0.000 claims abstract description 11
- -1 triton-100 Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 6
- 239000007987 MES buffer Substances 0.000 claims description 16
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000004005 microsphere Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000012982 microporous membrane Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 7
- 238000003149 assay kit Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a ceruloplasmin detection kit, which comprises a reagent R1 and a reagent R2; the components in the reagent R1 are as follows: PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000; the components in the reagent R2 are as follows: PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin. The invention also discloses a preparation method of the ceruloplasmin detection kit, which comprises the following steps: step a), preparation of reagent R1: adding purified water into a preparation tank A, sequentially adding each component of a reagent R1 into the preparation tank, mixing and stirring, adjusting the pH value of the solution, and filtering by using a microporous filter membrane to obtain the product; step B), preparation of reagent R2: adding purified water into the preparation tank B, sequentially adding the components of the reagent R2 into the preparation tank B, mixing and stirring the materials, and adjusting the pH value of the solution; filtering with microporous membrane. By adopting the scheme disclosed by the invention, the detection efficiency is improved, and the cost of clinical disease detection is reduced.
Description
Technical Field
The invention relates to a preparation method of a ceruloplasmin detection kit, in particular to a ceruloplasmin detection kit and a preparation method thereof.
Background
In urine detection, ceruloplasmin content detection is a conventional item of urine detection, and some clinical diseases can be judged by detecting the ceruloplasmin content in urine.
In particular, current clinical studies show that: the ceruloplasmin content in urine is influenced by the liver function, the kidney function and the gallbladder function of a human body, particularly, the liver can synthesize ceruloplasmin, and the biliary tract and the kidney are main ways for decomposing and removing ceruloplasmin, so that the detection of the ceruloplasmin content in urine has important clinical diagnosis significance for preventing and diagnosing some clinical diseases.
However, the current main clinical way to detect the binding force of ceruloplasmin still adopts the more traditional enzyme-linked immunosorbent assay.
The detection means is backward, the detection period is long, the detection cost is high, the cost of clinical detection is increased, and the detection efficiency is reduced.
Disclosure of Invention
The invention aims to solve the technical problem of providing a ceruloplasmin detection kit and a preparation method thereof.
The invention solves the technical problems through the following technical scheme:
a ceruloplasmin detection kit comprises a reagent R1 and a reagent R2;
the components and concentrations in the reagent R1 were as follows:
the components and concentrations in the reagent R2 were as follows:
PBS buffer solution 35-60mmol/L
The latex is coated with ceruloplasmin antibody solution 0.2-0.6%
Bovine serum albumin 15-30 mmol/L.
Preferably, the components and concentrations in the reagent R1 are as follows:
preferably, the components and concentrations in the reagent R1 are as follows:
preferably, the components and concentrations in the reagent R2 are as follows:
PBS buffer 50mmol/L
Latex-coated ceruloplasmin antibody solution 0.4%
Bovine serum albumin 22 mmol/L.
Preferably, the pH of the reagent R1 is between 7.2 and 8.5.
Preferably, the pH of the reagent R2 is between 7.2 and 8.5.
The invention also discloses a preparation method of the ceruloplasmin detection kit, which comprises the following steps:
step a), preparation of reagent R1:
adding purified water into a blending tank A, sequentially adding a PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000 into the blending tank, mixing and stirring, adjusting the pH of the solution to 7.8 in the mixing process, stirring the mixture until the solution is clarified, and filtering by using a microporous filter membrane to obtain a filtrate as a reagent R1;
step B), preparation of reagent R2:
adding purified water into a blending tank B, sequentially adding PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin into the blending tank B, mixing and stirring the materials until the solution is clear, and adjusting the pH value of the solution to 7.8;
and filtering the mixed solution by using a microporous filter membrane to obtain filtrate which is the reagent R2.
Preferably, the preparation method of the latex-coated ceruloplasmin antibody solution is as follows:
s1, putting latex microspheres with the particle sizes of 65nm and 120nm into MES buffer solution, adding EDAC solution, mixing uniformly, incubating for 1.5-2h at 37 ℃, centrifuging to remove supernatant, supplementing MES buffer solution until the volume is unchanged, incubating for 1.5-2h at 37 ℃, centrifuging again, and removing supernatant to obtain latex solution;
s2, adding a ceruloplasmin antibody and a polyethylene p-chloromethyl styrene copolymer mixed material on the basis of the latex solution obtained in the step S1, reacting for 1-3 hours, performing centrifugal precipitation, dispersing the precipitate in MES buffer solution, incubating for 1.5-2 hours at 37 ℃, centrifuging, dispersing and dissolving the precipitate in PBS buffer solution with half of the total volume of PBS buffer in a reagent R2, and sealing for 36-45 hours at 2-8 ℃ to obtain a latex-coated ceruloplasmin antibody solution.
Compared with the prior art, the invention has the following advantages:
the invention discloses a ceruloplasmin detection kit and a preparation method thereof, and the ceruloplasmin detection kit is successfully prepared by the technical scheme disclosed by the invention. The ceruloplasmin detection kit disclosed by the invention is applied to detecting the content of ceruloplasmin in urine, so that the content of ceruloplasmin in blood can be quickly and efficiently detected, the detection method disclosed by the invention is simple, the binding capacity of ceruloplasmin in urine can be quickly tested, the detection efficiency is improved, and the cost of clinical disease detection is reduced.
Detailed Description
The following examples are given for the detailed implementation and specific operation of the present invention, but the scope of the present invention is not limited to the following examples.
Example 1 ceruloplasmin assay kit
The ceruloplasmin detection kit comprises a reagent R1 and a reagent R2;
wherein, the components and the concentration in the reagent R1 are as follows:
the components and concentrations in reagent R2 were as follows:
PBS buffer 35mmol/L
Latex-coated ceruloplasmin antibody solution 0.2%
Bovine serum albumin 15 mmol/L.
Example 2 ceruloplasmin assay kit
The components and concentrations in the reagent R1 were as follows:
the components and concentrations in the reagent R2 were as follows:
PBS buffer solution 60mmol/L
Latex-coated ceruloplasmin antibody solution 0.6%
Bovine serum albumin 30 mmol/L.
Example 3 ceruloplasmin assay kit
The components and concentrations in the reagent R1 were as follows:
the components and concentrations in reagent R2 were as follows:
PBS buffer 50mmol/L
Latex-coated ceruloplasmin antibody solution 0.4%
Bovine serum albumin 22 mmol/L.
Example 4 preparation method of ceruloplasmin assay kit
In this example, reagent R1 and reagent R2 in example 1 are used as raw materials to prepare a ceruloplasmin detection kit by the following preparation method:
step a), preparation of reagent R1:
adding purified water into a blending tank A, sequentially adding a PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000 into the blending tank, mixing and stirring, adjusting the pH of the solution to 7.8 in the mixing process, stirring the mixture until the solution is clarified, and filtering by using a microporous filter membrane to obtain a filtrate as a reagent R1;
step B), preparation of reagent R2:
adding purified water into a blending tank B, sequentially adding PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin into the blending tank B, mixing and stirring the materials until the solution is clear, and adjusting the pH value of the solution to 7.8;
and filtering the mixed solution by using a microporous filter membrane to obtain filtrate which is the reagent R2.
The preparation method of the latex-coated ceruloplasmin antibody solution comprises the following steps:
s1, putting latex microspheres with the particle sizes of 65nm and 120nm into MES buffer solution, adding EDAC solution, mixing uniformly, incubating for 2h at 37 ℃, centrifuging to remove supernatant, adding MES buffer solution, adding the MES buffer solution until the volume is unchanged, incubating for h at 37 ℃, centrifuging to remove supernatant again, and obtaining latex solution;
s2, adding a ceruloplasmin antibody and a polyethylene p-chloromethyl styrene copolymer mixed material on the basis of the latex solution obtained in the step S1, reacting for 3 hours, centrifuging and precipitating, dispersing the precipitate in an MES buffer solution, incubating for 2 hours at 37 ℃, centrifuging, dispersing and dissolving the precipitate in one half of the total volume of a PBS buffer, and sealing for 40 hours at 6 ℃ to obtain a latex-coated ceruloplasmin antibody solution.
Example 5 preparation method of ceruloplasmin assay kit
In this embodiment, the reagent R1 and the reagent R2 in example 2 are used as raw materials, and the ceruloplasmin detection kit is prepared by the following preparation method:
step a), preparation of reagent R1:
adding purified water into a blending tank A, sequentially adding a PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000 into the blending tank, mixing and stirring, adjusting the pH of the solution to 7.8 in the mixing process, stirring the mixture until the solution is clarified, and filtering by using a microporous filter membrane to obtain a filtrate as a reagent R1;
step B), preparation of reagent R2:
adding purified water into a blending tank B, sequentially adding PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin into the blending tank B, mixing and stirring the materials until the solution is clear, and adjusting the pH value of the solution to 7.8;
and filtering the mixed solution by using a microporous filter membrane to obtain filtrate which is the reagent R2.
The preparation method of the latex-coated ceruloplasmin antibody solution comprises the following steps:
s1, putting latex microspheres with the particle sizes of 65nm and 120nm into MES buffer solution, adding EDAC solution, mixing uniformly, incubating for 1.5h at 37 ℃, centrifuging to remove supernatant, adding MES buffer solution until the volume is unchanged, incubating for 1.5h at 37 ℃, centrifuging again, and removing supernatant to obtain latex solution;
s2, adding a ceruloplasmin antibody and a polyethylene p-chloromethyl styrene copolymer mixture to react for 1-3h on the basis of the latex solution obtained in the step S1, centrifuging and precipitating, dispersing the precipitate in MES buffer solution, incubating for 2h at 37 ℃, centrifuging, dispersing and dissolving the precipitate in one half of the total volume of PBS buffer, and sealing for 42h at 8 ℃ to obtain a latex-coated ceruloplasmin antibody solution.
Example 6 preparation method of ceruloplasmin assay kit
In this embodiment, the reagent R1 and the reagent R2 in example 3 are used as raw materials to prepare a ceruloplasmin detection kit by the following preparation method:
step a), preparation of reagent R1:
adding purified water into a blending tank A, sequentially adding a PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000 into the blending tank, mixing and stirring, adjusting the pH of the solution to 7.8 in the mixing process, stirring the mixture until the solution is clarified, and filtering by using a microporous filter membrane to obtain a filtrate as a reagent R1;
step B), preparation of reagent R2:
adding purified water into a blending tank B, sequentially adding PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin into the blending tank B, mixing and stirring the materials until the solution is clear, and adjusting the pH value of the solution to 7.8;
and filtering the mixed solution by using a microporous filter membrane to obtain filtrate which is the reagent R2.
The preparation method of the latex-coated ceruloplasmin antibody solution comprises the following steps:
s1, putting latex microspheres with the particle sizes of 65nm and 120nm into MES buffer solution, adding EDAC solution, mixing uniformly, incubating for 1.7h at 37 ℃, centrifuging to remove supernatant, adding MES buffer solution until the volume is unchanged, incubating for 1.7h at 37 ℃, centrifuging again to remove supernatant to obtain latex solution;
s2, adding a ceruloplasmin antibody and a polyethylene p-chloromethyl styrene copolymer mixed material on the basis of the latex solution obtained in the step S1, reacting for 1h, performing centrifugal precipitation, dispersing the precipitate in an MES buffer solution, incubating for 2h at 37 ℃, centrifuging, dispersing and dissolving the precipitate in one half of the total volume of PBS buffer, and sealing for 38h at 6 ℃ to obtain a latex-coated ceruloplasmin antibody solution.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (8)
1. A ceruloplasmin detection kit is characterized by comprising a reagent R1 and a reagent R2;
the components and concentrations in the reagent R1 were as follows:
the components and concentrations in the reagent R2 were as follows:
PBS buffer solution 35-60mmol/L
The latex is coated with ceruloplasmin antibody solution 0.2-0.6%
Bovine serum albumin 15-30 mmol/L.
2. The ceruloplasmin detection kit according to claim 1, wherein the components and concentrations in said reagent R1 are as follows:
3. the ceruloplasmin detection kit according to claim 2, wherein the components and concentrations in said reagent R1 are as follows:
4. the ceruloplasmin detection kit according to claim 1, wherein the components and concentrations in said reagent R2 are as follows:
PBS buffer 50mmol/L
Latex-coated ceruloplasmin antibody solution 0.4%
Bovine serum albumin 22 mmol/L.
5. The ceruloplasmin detection kit according to claim 1 wherein said reagent R1 has a pH between 7.2 and 8.5.
6. The ceruloplasmin detection kit according to claim 1 wherein said reagent R2 has a pH between 7.2 and 8.5.
7. A method for preparing the ceruloplasmin detection kit of any one of claims 1 to 6 comprising the steps of:
step a), preparation of reagent R1:
adding purified water into a blending tank A, sequentially adding a PBS buffer solution, magnesium chloride, trehalose, triton-100, hydroxylamine hydrochloride, sodium azide and PEG-8000 into the blending tank, mixing and stirring, adjusting the pH of the solution to 7.8 in the mixing process, stirring the mixture until the solution is clarified, and filtering by using a microporous filter membrane to obtain a filtrate as a reagent R1;
step B), preparation of reagent R2:
adding purified water into a blending tank B, sequentially adding PBS buffer solution, latex-coated ceruloplasmin antibody solution and bovine serum albumin into the blending tank B, mixing and stirring the materials until the solution is clear, and adjusting the pH value of the solution to 7.8;
and filtering the mixed solution by using a microporous filter membrane to obtain filtrate which is the reagent R2.
8. The method for preparing a ceruloplasmin detection kit according to claim 7, wherein said latex-coated ceruloplasmin antibody solution is prepared by the following steps:
s1, putting latex microspheres with the particle sizes of 65nm and 120nm into MES buffer solution, adding EDAC solution, mixing uniformly, incubating for 1.5-2h at 37 ℃, centrifuging to remove supernatant, supplementing MES buffer solution until the volume is unchanged, incubating for 1.5-2h at 37 ℃, centrifuging again, and removing supernatant to obtain latex solution;
s2, adding a ceruloplasmin antibody and a polyethylene p-chloromethyl styrene copolymer mixed material on the basis of the latex solution obtained in the step S1, reacting for 1-3 hours, performing centrifugal precipitation, dispersing the precipitate in MES buffer solution, incubating for 1.5-2 hours at 37 ℃, centrifuging, dispersing and dissolving the precipitate in PBS buffer solution with half of the total volume of PBS buffer in a reagent R2, and sealing for 36-45 hours at 2-8 ℃ to obtain a latex-coated ceruloplasmin antibody solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010000861.5A CN111141913A (en) | 2020-01-02 | 2020-01-02 | Ceruloplasmin detection kit and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010000861.5A CN111141913A (en) | 2020-01-02 | 2020-01-02 | Ceruloplasmin detection kit and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111141913A true CN111141913A (en) | 2020-05-12 |
Family
ID=70523248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010000861.5A Pending CN111141913A (en) | 2020-01-02 | 2020-01-02 | Ceruloplasmin detection kit and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111141913A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113687075A (en) * | 2021-09-18 | 2021-11-23 | 北京安图生物工程有限公司 | Ceruloplasmin detection kit and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU991303A1 (en) * | 1980-06-26 | 1983-01-23 | Черновицкий Государственный Медицинский Институт | Ceruloplasmin activity determination method |
| JP2002284775A (en) * | 2001-03-27 | 2002-10-03 | Shino Test Corp | Method for stabilizing ascorbic acid or its salt in solution state, solution containing ascorbic acid or its salt and assay reagent for target substance to be assayed in sample |
| CN106501244A (en) * | 2016-09-30 | 2017-03-15 | 宁波普瑞柏生物技术股份有限公司 | Serum copper ions quantitative detecting reagent |
| CN107741494A (en) * | 2017-09-30 | 2018-02-27 | 安徽伊普诺康生物技术股份有限公司 | A kind of preparation method of CER detection kit |
| CN108303544A (en) * | 2017-01-13 | 2018-07-20 | 深圳开立生物医疗科技股份有限公司 | A kind of whole blood c reactive protein detection kit |
| CN110568206A (en) * | 2019-09-12 | 2019-12-13 | 苏州普瑞斯生物科技有限公司 | total iron binding force detection kit and preparation method thereof |
-
2020
- 2020-01-02 CN CN202010000861.5A patent/CN111141913A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU991303A1 (en) * | 1980-06-26 | 1983-01-23 | Черновицкий Государственный Медицинский Институт | Ceruloplasmin activity determination method |
| JP2002284775A (en) * | 2001-03-27 | 2002-10-03 | Shino Test Corp | Method for stabilizing ascorbic acid or its salt in solution state, solution containing ascorbic acid or its salt and assay reagent for target substance to be assayed in sample |
| CN106501244A (en) * | 2016-09-30 | 2017-03-15 | 宁波普瑞柏生物技术股份有限公司 | Serum copper ions quantitative detecting reagent |
| CN108303544A (en) * | 2017-01-13 | 2018-07-20 | 深圳开立生物医疗科技股份有限公司 | A kind of whole blood c reactive protein detection kit |
| CN107741494A (en) * | 2017-09-30 | 2018-02-27 | 安徽伊普诺康生物技术股份有限公司 | A kind of preparation method of CER detection kit |
| CN110568206A (en) * | 2019-09-12 | 2019-12-13 | 苏州普瑞斯生物科技有限公司 | total iron binding force detection kit and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113687075A (en) * | 2021-09-18 | 2021-11-23 | 北京安图生物工程有限公司 | Ceruloplasmin detection kit and preparation method thereof |
| CN113687075B (en) * | 2021-09-18 | 2024-03-12 | 北京安图生物工程有限公司 | Ceruloplasmin detection kit and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Culver et al. | Charged poly (N-isopropylacrylamide) nanogels for use as differential protein receptors in a turbidimetric sensor array | |
| CN103506093A (en) | Magnetic dual-template protein molecule imprinted nano particle and preparation method thereof | |
| CN111024962A (en) | Dissociating agent for detecting folic acid content from serum and detection method | |
| CN102675448B (en) | Method for isolating casein components in milk | |
| CN111141913A (en) | Ceruloplasmin detection kit and preparation method thereof | |
| CN109342743B (en) | Preparation method of denatured IgG capable of being efficiently combined with rheumatoid factor | |
| CN114164203B (en) | Extracellular vesicle purification material and purification method | |
| CN107290518B (en) | A kind of reagent for eliminating immune response false positive | |
| CN109507127A (en) | It is a kind of for detecting the kit of LBP content in human blood | |
| CN106188300A (en) | A kind of method for quickly purifying keeping bladder chalone C antibody-latex covalent coupling complex activity | |
| JP2006327962A (en) | Method for separating target substance and molecular complex | |
| Tsugo et al. | Specific Liberation of Non Protein Nitrogen from κ-Casein Fraction by Rennin and Pepsin | |
| CN111122882A (en) | Total iron detection kit and preparation method thereof | |
| CN109021066A (en) | A kind of method of broth extraction glutathione | |
| CN113234182B (en) | Beta-cyclodextrin arm lectin magnetic material and preparation method and application thereof | |
| CN114906876A (en) | Preparation method of ferroferric oxide magnetic beads based on polyvinyl alcohol modification | |
| CN112246222B (en) | Virus enrichment material, preparation method and application thereof, virus enrichment system and application thereof | |
| CN112898624B (en) | Alternative template imprinted polymer for specifically recognizing exosomes and application thereof | |
| EP0713094B1 (en) | Heterogeneous immunoassay with precipitable solid phase | |
| CN112782409A (en) | Kit for determining IV type collagen in human blood and detection method | |
| CN105693922A (en) | Amphiprotic protein ice gel imprinted polymer, and preparation method and application thereof | |
| CN112051401A (en) | Pepsinogen's assay kit | |
| CN1314952C (en) | Sample treatment agent used on solid phase membrane immune analysis method mobile phase | |
| CN110218693A (en) | For extracting reagent combination, kit and the method for excretion body | |
| CN1755366A (en) | IgG detection reagent for mixed agglutination reaction of sperm membrane surface antibody, and immuno-microsphere preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200512 |
|
| WD01 | Invention patent application deemed withdrawn after publication |